BioCentury | Apr 26, 2010
Company News

Chiesi, Vernalis deal

...disclosed in its FY09 earnings that it will return rights to Chiesi this quarter for V1512...
...ester prodrug of levodopa, and carbidopa to treat Parkinson's disease (PD) in 2008. Vernalis acquired V1512...
...Cita NeuroPharmaceuticals Inc., which licensed exclusive, worldwide rights from Chiesi. The deal excluded Italy, where V1512...
BioCentury | Sep 1, 2008
Clinical News

V1512: Phase II data

...In a Phase II pharmacokinetic study, V1512 showed an improved reproducibility and reliability of levodopa absorption...
...trial for V1512 has received an SPA from FDA. Vernalis plc (LSE:VER), Winnersh, U.K. Product: V1512...
BioCentury | Feb 25, 2008
Company News

Endo, Vernalis cancer, cardiovascular, neurology news

...a partner. The company has six compounds in the clinic, four of which are unpartnered: V1512...
BioCentury | Feb 21, 2008
Company News

Vernalis up on restructuring plans, settlement

...a partner. The company has six compounds in the clinic, four of which are unpartnered: V1512...
BioCentury | Jul 2, 2007
Finance

3Q Financial Markets Preview: Waiting for the Fall

...include short term prevention of menstrual migraine. VER expects to start Phase III trials of V1512...
BioCentury | Nov 21, 2005
Company News

Cita NeuroPharmaceuticals Inc., Vernalis deal

...shareholders up to $35 million in stock or cash, contingent upon certain milestones for Cita's CNP1512...
...Parkinson's disease (PD) and CNP3381 to treat neuropathic pain. Cita has exclusive worldwide rights to CNP1512...
BioCentury | Nov 19, 2005
Top Story

Vernalis to acquire Cita

...shareholders up to $35 million in stock or cash, contingent upon certain milestones for Cita's CNP1512...
...Parkinson's disease (PD) and CNP3381 to treat neuropathic pain. Cita has exclusive worldwide rights to CNP1512...
BioCentury | Aug 22, 2005
Finance

Ebb & Flow

...was seeking to raise up to C$35 million ($29.2 million). The company's lead compound is CNP1512...
BioCentury | Aug 16, 2005
Financial News

Cita postpones IPO to discuss acquisition

...up to C$35 million ($27.8 million) in an IPO. Cita has exclusive worldwide rights to CNP1512...
BioCentury | Feb 7, 2005
Company News

GB Therap, Chiesi Farmaceutici SpA deal

...GB acquired exclusive worldwide rights to Chiesi's CHF1512 to treat Parkinson's disease (PD), excluding Italy. The...
...fee and is eligible for milestones. Chiesi also will make an equity investment in GB. CHF1512...
Items per page:
1 - 10 of 10